U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT06809530) titled 'Intrathecal Double Checkpoint Inhibition in Combination with Pemetrexed' on Jan. 26.
Brief Summary: The objective of the present study is to evaluate the tolerability, feasibility, safety and therapeutic response of intrathecal administration of double checkpoint inhibition(QL1706) in combination with pemetrexed in patients with leptomeningeal metastasis.
Study Start Date: March 01
Study Type: INTERVENTIONAL
Condition:
Leptomeningeal Metastasis
Intervention:
DRUG: QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
Iparomlimab and Tuvonralimab (QL1706)Intrathecal injection of 50 mg PD-1/CTLA-4 bispecific antibody was admini...